Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.
Find out how Strive’s acquisition of Semler Scientific strengthens its diagnostic and patient monitoring capabilities in the regulated medical device market.
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.
Find out how Vaxart’s oral bivalent norovirus vaccine induced immune responses in lactating women and enabled antibody transfer to breastfed infants.
Find out how AAVantgarde Bio’s fully enrolled LUCE-1 Phase 1/2 trial advances AAVB-081 gene therapy development for Usher syndrome-related retinitis pigmentosa.
Swissmedic approves Santhera’s AGAMREE for Duchenne muscular dystrophy. Find out how vamorolone could reshape long-term steroid treatment strategies.
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.
Find out how positive interim ADAPT trial data for CELZ-201 may signal a turning point in regenerative, non-opioid treatment approaches for chronic lower back pain.